P731.F MEDEXUS PHARMACEUTIC.
- Market cap
- EUR 111M
- P/E
- -
- P/B
- 2.34x
- ROE
- 4.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is P731.F undervalued?
Graham numberThe Graham number of MEDEXUS PHARMACEUTIC. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MEDEXUS PHARMACEUTIC. fundamental analysis
No fundamental analysis for MEDEXUS PHARMACEUTIC. yet.
MEDEXUS PHARMACEUTIC. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MEDEXUS PHARMACEUTIC.
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile id…
Full company profileMEDEXUS PHARMACEUTIC. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MEDEXUS PHARMACEUTIC. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 76.7M | 108M | 113M | 108M | 99.3M | 114M |
| Gross Profit | 37.9M | 60.0M | 59.5M | 56.6M | 54.4M | 63.6M |
| Operating Income | -12.4M | 8.49M | 12.8M | 11.9M | 5.84M | 8.46M |
| EBITDA | - | 14.6M | 19.3M | 16.8M | 12.7M | 16.7M |
| Net Income | -2.88M | 1.22M | -214K | 2.25M | -2.39M | 2.18M |
| EPS | -0.14 | 0.06 | -0.01 | 0.07 | -0.07 | 0.07 |
| Balance Sheet | ||||||
| Total Assets | 139M | 161M | 156M | 172M | 147M | 142M |
| Total Liabilities | 121M | 139M | 125M | 120M | 98.3M | 94.0M |
| Shareholders' Equity | 17.8M | 22.4M | 30.3M | 52.1M | 49.0M | 48.1M |
| Cash & Short-term Investments | 10.0M | 13.1M | 5.26M | 24.0M | 6.52M | 5.34M |
| Cash Flow | ||||||
| Operating Cash Flow | -1.18M | -1.44M | 18.7M | 24.0M | 18.9M | -2.91M |
| Capital Expenditure | 7.71M | 362K | 266K | 2.73M | 15.2M | 88.0K |
| Free Cash Flow | -8.89M | -1.81M | 18.4M | 21.3M | 3.72M | -3.00M |
| Ratios | ||||||
| ROE | -16.2% | 5.4% | -0.7% | 4.3% | -4.9% | 4.5% |
| ROA | -2.1% | 0.8% | -0.1% | 1.3% | -1.6% | 1.5% |
| Net Profit Margin | -3.8% | 1.1% | -0.2% | 2.1% | -2.4% | 1.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MEDEXUS PHARMACEUTIC. dividends
MEDEXUS PHARMACEUTIC. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:15 on Dec 19, 2018.
Who owns MEDEXUS PHARMACEUTIC.
- Insiders 8.02%
- Institutions 3.45%
- Public & others 88.53%
- Shares outstanding 31.4M
- Free float 28.9M
MEDEXUS PHARMACEUTIC. company profile
- Company name
- MEDEXUS PHARMACEUTIC.
- Ticker
- P731.F
- ISIN
- CA58410Q2036
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 90
- Fiscal year end
- March
- Address
- 10 King Street East, Toronto, ON, Canada, M5C 1C3
- Phone
- 877 422 5242
- Website
- medexus.com
About MEDEXUS PHARMACEUTIC.
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
MEDEXUS PHARMACEUTIC. management
9- Mr. Kenneth d'EntremontCEO & Director
- Mr. Brendon BuschmanChief Financial Officer
- Mr. Ian C. Wildgoose BrownGeneral Counsel & Corporate Secretary
- Mr. William T. PoncySenior Vice President of Commercial Operations - United States
- Ms. Toshiye IshisakaVice President of Global Operations & Compliance
- Ms. Tina Byers CFAExecutive of Investor Relations
- Ms. Meaghan WasylykVice President of Human Resources
- Ms. Theresa AnkamahVice President & Head of Medical Affairs
- Mr. Ata MiyarHead of Business Development